Articles from Scipher Medicine

Scipher Medicine, a leader in precision immunology, and Savant Bio, a Roivant-backed health data infrastructure company, today announced an expanded strategic partnership to build the world’s most advanced clinicogenomic dataset in rheumatoid arthritis (RA). The collaboration aims to generate high-resolution insights to support academic research, clinical trial design, therapeutic strategy, and real-world evidence generation.

At the European Congress of Rheumatology (EULAR) 2025, Scipher Medicine, the company behind the groundbreaking PrismRA® test, unveiled a new, AI-driven approach to help doctors better evaluate if a rheumatoid arthritis (RA) treatment is truly working — a challenge that has long frustrated both patients and physicians.

Scipher Medicine, a leading precision immunology company, today announced a strategic alliance with Grupo Amarey, a leading company in the representation and distribution of technologies, solutions, and services for the healthcare sector in Colombia, Panama, and Costa Rica, to expand the global reach of its innovative precision diagnostic, PrismRA®. This collaboration marks Scipher Medicine’s first international expansion, bringing personalized medicine solutions to patients with rheumatoid arthritis (RA) in Latin America, starting with Colombia.

Scipher Medicine, a precision immunology company dedicated to transforming patient care through data-driven insights, today announced a strategic collaboration with a top 3 global pharmaceutical company. The partnership aims to enhance clinical trials by incorporating PrismRA®, Scipher's proprietary precision medicine diagnostic, into an ongoing trial.

Scipher Medicine, a leader in precision medicine for autoimmune diseases, and Kythera Labs, a leading healthcare data and technology company, announced a partnership to advance rheumatology treatment discovery. The integration of Scipher’s real-world clinical and genomic data (biobank) insights with Kythera’s enriched high-fidelity multi-source data assets will empower Scipher to further leverage this unique data derived from PrismRA® for precision medicine diagnostics. Kythera’s technology and proprietary patient mastering algorithms enable privacy protection while maximizing the value of data assets, achieving a 98% match rate to Scipher’s data, helping to bring together real-world data (RWD) sources targeted to disease-specific therapeutic areas, and enabling new insights for researchers.

Scipher Medicine, a leader in precision medicine for autoimmune diseases, and Roivant, a global biopharmaceutical company that aims to improve the lives of patients by accelerating the development and commercialization of medicines that matter, today announced a strategic partnership to advance rheumatology drug discovery and development by integrating Scipher’s real-world clinical and genomic data insights into Roivant’s research and development efforts. This collaboration will leverage Scipher's unique data and intelligence derived from its PrismRA® precision medicine diagnostic. Financial terms were not disclosed.

Scipher Medicine, a company focused on proprietary AI and network biology platform solutions to transform patient care, has launched a new approach to develop biomarkers following the publication of the novel, patent-pending framework PRoBeNet (Predictive Response Biomarkers using Network medicine).

Scipher Medicine, a company focused on proprietary AI and network biology platform solutions to transform patient care, is attending and presenting at the annual European Alliance of Associations for Rheumatology (EULAR) conference in Vienna, Austria.

Scipher Medicine, an AI-enabled precision immunology company, today announced the appointment of Reginald Seeto, MBBS*, as Chief Executive Officer and President. Scipher developed SpectraTM, a proprietary AI platform that has been used to build both an autoimmune diagnostic and an emerging biopharmaceutical business. In the diagnostics business, PrismRA® was recently approved by MolDx for therapy selection in rheumatoid arthritis patients, and in the biopharmaceutical business, recent deals have focused on generating novel target discovery and data insights for partners.

Scipher Medicine today announced that it has entered into a multi-disease area collaboration with Ionis Pharmaceuticals. In the collaboration, Ionis is responsible for advancing, developing and commercializing oligonucleotide therapies directed to targets discovered by Scipher’s Spectra™ platform.

Scipher Medicine, a precision immunology company matching each patient with their most effective therapy, has acquired Philadelphia-based data, analytics, and software company CrossBridge to bolster its data and analytics capabilities.

Scipher Medicine announced data validating the clinical utility of the company’s PrismRA test for guiding treatment selection for rheumatoid arthritis (RA) patients. The latest publication in the Expert Review of Molecular Diagnostics showed that patients whose care included PrismRA testing had significantly superior clinical outcomes when compared to current standard of care (SOC).

Scipher Medicine today announced that Galapagos (Euronext & NASDAQ: GLPG) has exercised its option to in-license novel drug targets for inflammatory bowel disease (IBD) discovered by Scipher’s Spectra™ platform.

Scipher Medicine, a precision immunology company matching each patient with their most effective therapy, today announced new data showing patients with rheumatoid arthritis (RA) whose treatment was informed by PrismRA had improved clinical outcomes and use of PrismRA could reduce health care spending. The data were published in Expert Opinion on Biological Therapy.

Scipher Medicine, a precision immunology company matching each patient with their most effective therapy, today announced the completion of a $110 million financing. The round is led by Cowen Healthcare Investments, with participation from new investors Neuberger Berman, Hitachi Ventures, Laurion Capital, and Monashee Investment Management. Existing investors Northpond Ventures, aMoon, Khosla Ventures, Optum Ventures, Echo Health Ventures, and Alumni Ventures also are participating. To date, Scipher has raised $227 million.

Scipher Medicine, a precision immunology company matching each patient with their most effective therapy, today announced that Chief Financial Officer John Strumbos will participate in the virtual 11th Annual SVB Leerink Global Healthcare Conference, hosting investor meetings on Tuesday, February 15.

Scipher Medicine, a precision immunology company matching each patient with their most effective therapy, today announced new clinical utility data for its PrismRA blood test were published in Expert Review of Molecular Diagnostics. The real-world results show that patients with rheumatoid arthritis (RA) have significantly improved clinical response when PrismRA is used to select treatment. PrismRA is the only blood test in the market informing personalized treatment decisions for patients with RA.

Scipher Medicine, a precision immunology company matching each patient with their most effective therapy, today announced that Alif Saleh, chief executive officer, will present at the 40th Annual J.P. Morgan Healthcare Conference on Wednesday, January 12, 2022, at 8:30 a.m. ET.

Scipher Medicine, a precision immunology company matching each patient with their most effective therapy, today announced the appointment of Richard Blackburn to its advisory board.

Scipher Medicine, a precision immunology company matching patients with their most effective therapy, today announced that nearly 15 percent of prescribing U.S. rheumatologists have used PrismRA since its launch a year ago, resulting in lowered healthcare costs and improved patient outcomes. PrismRA is the only blood test in the market informing personalized treatment decisions for patients with rheumatoid arthritis (RA).

Scipher Medicine, a precision immunology company matching patients with their most effective therapy, today announced the appointment of Michael Elliott, MBBS, PhD, FRACP, as scientific advisor. Dr. Elliott is a physician-scientist and pioneer in drug development for autoimmune diseases.

Scipher Medicine, a precision immunology company matching patients with their most effective medication therapies, today announced the appointment of Sam Asgarian, M.D., MBA, as chief medical officer.

Scipher Medicine, a precision immunology company matching patients with their most effective medication therapies, today announced a partnership with RxParadigm, a pharmacy benefit manager company delivering transparency and restoring competitiveness to healthcare systems, to offer RxParadigm customers access to PrismRA. PrismRA is the only molecular signature blood test available in the U.S. that informs personalized treatment decisions for patients with rheumatoid arthritis (RA).

Scipher Medicine, a precision immunology company matching patients with their most effective therapies, today announced that Alif Saleh, Chief Executive Officer, and John Strumbos, Chief Financial Officer, will participate in the Jeffries London Healthcare Conference, November 16-19.

Scipher Medicine, a precision immunology company matching patients with their most effective therapies, today announced that Alif Saleh, Chief Executive Officer, and John Strumbos, Chief Financial Officer will present at the Canaccord Genuity Virtual MedTech, Diagnostics and Digital Health & Services Forum on Thursday, November 18, 2021, at 9:00 a.m. ET, and will participate in one-on-one investor meetings.

GNS Healthcare, an artificial intelligence company creating in silico patients that simulate drug treatment at the individual patient level, and Scipher Medicine, a precision immunology company matching patients with the most effective therapy, today announced plans to develop and launch Gemini — The in silico Patient™ for rheumatoid arthritis (RA), to help patients reach target treatments sooner.

TARA Biosystems, a biotechnology company harnessing human biology and data to transform cardiac drug discovery, today announced a collaboration with Scipher Medicine, a precision medicine company matching patients with the most effective therapy. The collaboration will address a critical unmet need for effective therapeutics in cardiac laminopathies.